Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.

Autor: Pothuri B; GOG Foundation and Departments of Obstetrics/Gynecology and Medicine, Division of Gynecologic Oncology, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. Electronic address: Bhavana.pothuri@nyulangone.org., Han S; Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium., Chase DM; Department of Obstetrics and Gynecology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA., Heitz F; AGO Study Group, Department for Gynaecology and Gynaecologic Oncology, Kliniken Essen- Mitte, Essen, Germany; Department of Gynaecology, Charité-Universitätsmedizin Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; and Berlin Institute of Health, Berlin, Germany., Burger RA; Department of Obstetrics & Gynecology, University of Pennsylvania, Philadelphia, PA, USA., Gaba L; Medical Oncology Department, Hospital Clinic de Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain., Van Le L; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Guerra E; Medical Oncology Department, Breast and Gynaecological Cancer Unit, Hospital Ramón y Cajal, Madrid, Spain., Bender D; Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, USA., Korach J; Gynecologic Oncology Department, The Chaim Sheba Medical Center, Sackler Medical School, Tel Aviv University, Ramat Gan, Israel., Cloven N; Texas Oncology, Fort Worth, TX, USA., Churruca C; Medical Oncology Department, Hospital Universitario Donostia, San Sebastian, Spain., Follana P; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Département D'oncologie Médicale, Centre Antoine Lacassagne, Nice, France., DiSilvestro P; Department of Obstetrics and Gynecology, Women and Infants Hospital/Alpert School of Medicine at Brown University, Providence, RI, USA., Baurain JF; Medical Oncology Departement, Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium., Jardon K; Department of Obstetrics and Gynecology, McGill University, Montreal, QC, Canada., Pisano C; Department of Urology and Gynaecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy., Peen U; Herlev University Hospital, Herlev, Denmark., Mäenpää J; NSGO and Tampere University, Tampere, Finland., Gupta D; GSK, Waltham, MA, USA., Bacqué E; GSK, Waltham, MA, USA., Li Y; GSK, Waltham, MA, USA., Compton N; GSK, London, United Kingdom., Antonova J; GSK, Waltham, MA, USA., Monk BJ; HonorHealth Research Institute, University of Arizona College of Medicine, Phoenix, and Creighton University School of Medicine, Phoenix, AZ, USA., González-Martín A; Medical Oncology Department and Program in Solid Tumours - CIMA, Cancer Center Clínica Universidad de Navarra, Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2024 May; Vol. 184, pp. 168-177. Date of Electronic Publication: 2024 Feb 06.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Autor: Vergote, I. Scambia, G. O'Malley, D.M. Van Calster, B. Park, S.-Y. del Campo, J.M. Meier, W. Bamias, A. Colombo, N. Wenham, R.M. Covens, A. Marth, C. Raza Mirza, M. Kroep, J.R. Ma, H. Pickett, C.A. Monk, B.J. Park, S.Y. Song, Y.S. Makarova, Y. Trinidad, J. Ngan, H.Y.S. Aravantinos, G. Nam, J.-H. Gorbunova, V. Krikunova, L. Bae, D.-S. Arija, J.A.A. Mirza, M.R. Zamagni, C. Papandreou, C. Raspagliesi, F. Lisyanskaya, A. Benzaquen, A.O. Tognon, G. Ortega, E. Herraez, A.C. Buscema, J. Green, A. Burger, R. Sakaeva, D. Sanchez, A.R. Ghamande, S. King, L. Petru, E. Peen, U. Takeuchi, S. Ushijima, K. Martin, A.G. Kamelle, S. Carney, M. Forget, F. Bentley, J. Sehouli, J. Zola, P. Kato, H. Fadeeva, N. Gotovkin, E. Vladimirov, V. Marin, M.R. Alia, E.G. Shahin, M. Bhoola, S. Tewari, K. Anderson, D. Honhon, B. Pelgrims, J.G. Oza, A. Jimenez, J.G.-D. Hansen, V. Benjamin, I. Renard, V. Van den Bulck, H. Haenle, C. Koumakis, G. Yokota, H. Popov, V. Bradley, W. Wenham, R. Reid, R. McNamara, D. Friedman, R. Barlin, J. Spirtos, N. Chapman, J. Sevelda, P. Huizing, M. Lamot, C. Goffin, F. Hondt, L.D. Covens, A. Spadafora, S. Rautenberg, B. Reimer, T. Möbus, V. Hilpert, F. Gropp-Meier, M. Savarese, A. Pignata, S. Verderame, F. Mizuno, M. Takano, H. Ottevanger, P. Velasco, A.P. Palacio-Vazquez, I. Law, A. McIntyre, K. Teneriello, M. Fields, A. Lentz, S. Street, D. Schwartz, B. Mannel, R. Lim, P. Pulaski, H. Janni, W. Zorr, A. Karck, U. Cheng, A.C.K. Sorio, R. Gridelli, C. Aoki, D. Oishi, T. Hirashima, Y. Boere, I. Ferrer, E.F. Braly, P. Wilks, S. Lee, C. Schilder, J. Veljovich, D. Secord, A. Davis, K. Rojas-Espaillat, L. Lele, S. DePasquale, S. Squatrito, R. Schauer, C. Dirix, L. Vuylsteke, P. Joosens, E. Provencher, D. Lueck, H.-J. Hein, A. Burges, A. Canzler, U. Park-Simon, T.-W. Griesinger, F. Gadducci, A. Alabiso, O. Okamoto, A. Sawasaki, T. Saito, T. Ibañez, A.H. Calomeni, C. Spillman, M. Choksi, J. Taylor, N. Muller, C. Moore, D. DiSilvestro, P. Cunningham, M. Rose, P. Oppelt, P. Verhoeven, D. Graas, M.-P. Ghatage, P. Tonkin, K. Kurzeder, C. Schnappauf, B. Müller, V. Schmalzrie, H. Kalofonos, H. Bruzzone, M. Kroep, J. Diaz, C.C. Garcia, J.M. Polo, S.H. Garrison, M. Rocconi, R. Andrews, S. Bristow, R. McHale, M. Basil, J. Houck III, W. Bell, M. Cosin, J. Modesitt, S. Kendrick, J. Wade III, J. Wong, C. Evans, A. Buekers, T. Vanderkwaak, T. Ferriss, J. Darus, C. DAndre, S. Higgins, R. Monk, B. Bakkum-Gamez, J. DeMars, L. Van Le, L. Puls, L. Trehan, S. LaPolla, J. Michelson, E.D. Merchant, J. Peterson, C. Reid, G. Seago, D. Zweizig, S. Gajewski, W. Panwalkar, A. Leikermoser, R. Bogner, G. Debruyne, P. D'hondt, R. Berteloot, P. Kerger, J. Biagi, J. Castonguay, V. Welch, S. Muhic, A. Heubner, M. Grischke, E.-M. Rack, B. Fleisch, M. Lordick, F. Pectasides, D. Ho, W.M. Selvaggi, L. Vasquez, F.M. Villanueva, W.O.B. Alavez, A.M. Kessels, L. Bertran, A.S. Fernandez, C.M. Fabregat, M.B. Del Prete, S. Elkas, J. Cecchi, G. Kumar, P. Huh, W. Messing, M. Karimi, M. Kelley, A. Edraki, B. Mutch, D. Leiserowitz, G. Anderson, J. Lentz, S. Chambers, S. Morris, R. Waggoner, S. Gordon, A. Method, M. Johnson, P. Lord, R. Drake, J. Sivarajan, K. Midathada, M. Rice, K. Wadsworth, T. Pavelka, J. Edwards, R. Miller, D.S. Ford, P.L. Hurteau, J. Bender, D. Schimp, V. Creasman, W. Lerner, R. Chamberlain, D. Kueck, A. McDonald, J. Malad, S. Robinson-Bennett, B. Davidson, S. Krivak, T. Lestingi, T. Arango, H. Berard, P. Finkelstein, K. Gaur, R. Krasner, C. Ueland, F. Talmage, L. Yamada, S. Sutton, G. Potkul, R. Prasad-Hayes, M. Osborne, J. Celano, P. Thigpen, J. Sharma, S. Schilder, R. Tammela, J. Kemeny, M. Brown, A. Eisenhauer, E. Williams, J. Rowland, K. Nahum, K. Burke, J. Dar, Z. Fleming, N. Gibb, R. Guirguis, A. Herzog, T. John, V. Kumar, S. Kamat, A. Kassar, M. Leitao, M. Levine, L. Mendez, L. Patel, D. Berry, E. Warshal, D. Wolf, J. Zarwan, C. Collins, Y. Spitzer, G. Miller, B. Einstein, M. TRINOVA-3/ENGOT-ov2/GOG-3001 investigators

Background: Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown promise in the treatment of ovarian cancer. We aimed to assess whether tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::f5b2506ee3f2e023ab2df41ece4fbd26
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3105962

810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial

Autor: Pothuri, B., Han, S., Chase, D., Heitz, F., Burger, R., Gaba, L., Van Le, L., Guerra, E., Bender, D., Korach, J., Cloven, N.G., Follana, P., Baurain, J-F., Pisano, C., Peen, U., Maenpaa, J., Bacqué, E., Li, Y., Martín, A. González, Monk, B.J.

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S612-S613

Correction to: “Safety and dose modification for patients receiving niraparib”

Autor: Berek, J.S., Matulonis, U.A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I., Rosengarten, O., Ledermann, J., Pineda, M., Ellard, S., Sehouli, J., Gonzalez-Martin, A., Berton-Rigaud, D., Madry, R., Reinthaller, A., Hazard, S., Guo, W., Mirza, M.R.

Publikováno v: In Annals of Oncology May 2019 30(5):859-859

Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study.

Autor: Hiroaki Itamochi¹, Nobuhiro Takeshima², Junzo Hamanishi³, Kosei Hasegawa⁴, Motoki Matsuura⁵, Kiyonori Miura⁶, Shoji Nagao⁷, Hidekatsu Nakai⁸, Naotake Tanaka⁹, Hideki Tokunaga^10,11, Shin Nishio¹², Hidemichi Watari¹³, Yoshihito Yokoyama¹⁴, Yoichi Kase¹⁵, Shuuji Sumino¹⁶, Ai Kato¹⁷, Ajit Suri¹⁸, Toshiaki Yasuoka¹⁹ tyasuoka.m.ehimeuniv@gmail.com, Kazuhiro Takehara¹⁹

Publikováno v: Journal of Gynecologic Oncology. Sep2024, Vol. 35 Issue 5, p1-12. 12p.